ArticleCellular & molecular immunology2020
Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.
Article in Cellular & molecular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 72 citations in OpenAlex.
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Humoral immunity in cancer.Signal transduction and targeted therapy · 2026Review
- Integrating multi-omics analysis and machine learning to refine molecular subtypes and prognostic assessment of lower-grade glioma.Molecular therapy. Oncology · 2026Article
- Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment.International journal of molecular sciences · 2026Review
- Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma.Journal of translational internal medicine · 2026Article
- Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer.Cell reports. Medicine · 2026Article
- St6gal1-mediated sialylation protects retinal ganglion cells by restraining microglial phagocytosis.Journal of neuroinflammation · 2026Article
- Prognostic performance of baseline serum immunoglobulin G in patients with metastatic renal cell carcinoma receiving first-line ICI-TKI therapy.Frontiers in oncology · 2026Article
- Immunoglobulin G in aging and cancer.Frontiers in immunology · 2026Review
- Sialylation in Thyroid Carcinoma: An Overview of Mechanisms, Markers, and Therapeutic Opportunities.Journal of Cancer · 2026Review
- Preclinical pharmacokinetic modeling and clinical translation of SIG001, a novel anti-cancer therapeutic antibody targeting on cancer-derived sialylated IgG.Frontiers in pharmacology · 2026Article
- The role and potential mechanism of immunoglobulin G N-glycosylation in gastrointestinal tumors.Medical molecular morphology · 2025Review
- Mandatory preventive vaccines for infectious diseases expressing T-cell epitopes for cancer prevention.Infectious agents and cancer · 2025Article
- A dynamic molecular landscape in colorectal cancer progression at single-cell resolution.Journal of translational medicine · 2025Article
- Sialylated IgG expressed in triple-negative breast cancer cells promotes cancer progression by promoting glycolysis.Breast cancer research : BCR · 2025Article
- Sialylated IgG-activated integrin β4-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis.Neoplasia (New York, N.Y.) · 2025Article
- B-cells and non-B-cells immunoglobulins expression in canine perianal gland tumours: a preliminary study.Frontiers in veterinary science · 2025Article
- Quantitative N-glycoproteomic analysis reveals glycosylation signatures of plasma immunoglobulin G in systemic sclerosis.Frontiers in immunology · 2025Article
- Sialylated Immunoglobulin G Promotes the Malignant Progression of Oral Squamous Cell Carcinoma through VCP-Mediated NDUFB6 Stabilization Regulated Mitochondrial Oxidative Phosphorylation.Research (Washington, D.C.) · 2025Article
- Current status and future prospects of cancer-derived immunoglobulins in pancreatic cancer.Journal of Cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, IgG in the tumor microenvironment (TME) has been considered a product of B cells and serves as an antitumor antibody. However, in this study, using a monoclonal antibody against cancer-derived IgG (Cancer-IgG), we found that cancer cells could secrete IgG into the TME. Furthermore, Cancer-IgG, which carries an abnormal sialic acid modification in the CH1 domain, directly inhibited effector T-cell proliferation and significantly promoted tumor growth by reducing CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.